

技術分析



分析師

大中華區研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

藥明生物 (2269 HK)

最後價格:	港幣 50.70 元
支撐位:	港幣 47.80 元/港幣 44.40 元
阻力位:	港幣 57.85 元/港幣 63.95 元

技術分析:

价格行为成功维持在“阻力转支撑”区域上方，确认了结构性极性转换的有效性，并确保了一高维度上行趋势的完整性。这一关键防线上的持续企稳，表明多头对局部回踩抛压完成了良性吸收。技术动能进一步验证了这一建设性格局，RSI 指标稳稳运行于 50 中轴线上方，展现出强劲且持续的买方控制力。只要多头在后续盘整中持续守住这一核心支撑锚点，最小阻力路径将继续指向价格向上拓展，驱动主升波段向更高的目标位延伸。

平均時限：約兩週。



翰森製藥 (3692 HK)

最後價格:	港幣 35.96 元
支撐位:	港幣 33.42 元/港幣 31.74 元
阻力位:	港幣 40.12 元/港幣 43.94 元

技術分析:

价格行为成功守住了大跳空缺口支撑区下轨，确认了这一核心结构性底座的有效性，并展现出强劲的需求端动能留存。价格在开盘缺口这一流动性真空区上方的持续企稳，表明机构资金对局部抛压完成了良性吸收而非筹码派发。技术动能进一步印证了这一建设性格局，RSI 指标稳稳运行于 50 中轴线上方。一旦价格向上有效贯穿 HK\$36.94 的前线波段高点，将彻底清除上方残余阻力，为迈向更高的第一阶段主要目标位打开持续的上行空间。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."